Amgen to Web Investor Call at EADV 2021 | New
THOUSAND OAKS, California., September 29, 2021 / PRNewswire / – Amgen (NASDAQ: AMGN) will host an investor community conference call in conjunction with the 2021 Congress of the European Academy of Dermatology and Venereology (EADV). Monday, October 4, 2021 at 8:30 a.m.ET, David M. Reese, MD, executive vice president of research and development at Amgen, along with other members of Amgen’s leadership team, will discuss clinical data presented at EADV, including trial data phase 2 AMG 451 / KHK4083 in patients with atopic dermatitis, as well as our broader inflammation portfolio.
Live audio of the call for investors will be simultaneously broadcast over the Internet and will be available to members of the media, investors and the general public.
The webcast, along with other selected presentations on the evolution of Amgen’s business given at certain investor and medical conferences, is available on Amgen’s website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability, and webcast links are noted in Amgen’s Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.
Amgen is committed to unlocking the potential of biology for critically ill patients by discovering, developing, manufacturing and delivering innovative human therapies. This approach begins with the use of tools such as advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas where unmet medical needs are high and leverages its expertise to seek solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown into one of the world’s leading independent biotechnology companies, reaching millions of patients around the world, and developing a drug pipeline with disruptive potential.
For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.
CONTACT: Amgen, Thousand Oaks
Michael Strapazon, 805-313-5553 (media)
Trish rowland, 805-447-5631 (media)
Arvind Sood, 805-447-1060 (investors)
View original content to download multimedia: https://www.prnewswire.com/news-releases/amgen-to-webcast-investor-call-at-eadv-2021-301388248.html